Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine, Inc. (Nasdaq: HYPR) is a health technology and medical device company that focuses its news flow on developments around the Swoop® Portable MR Imaging® System, an FDA-cleared, portable, ultra-low-field brain MRI platform. Company press releases emphasize regulatory milestones, clinical studies, financial results, and global health initiatives tied to this AI-powered portable MRI technology.
Investors and clinicians following HYPR news can expect regular updates on clinical research and indication expansion efforts. Recent announcements include the enrollment of the first patient in the Contrast PMR study, a prospective, multi-center trial designed to evaluate contrast-enhanced ultra-low-field portable MRI to support a future FDA submission for expanded intended use of the Swoop® system with gadolinium-based contrast agents. Other clinical news has highlighted the PRISM PMR study, which evaluates the Swoop® system’s use in neurosurgical operating room settings, and a peer-reviewed publication describing the economic impact of integrating the Swoop® system into acute hospital care.
Hyperfine’s news feed also features regulatory and market access updates, such as regulatory approval of the Swoop® system in India by the Central Drugs Standard Control Organization (CDSCO), as well as CE Mark and UKCA Mark approvals for its Optive AI™ software. Financial and corporate news includes quarterly and preliminary unaudited financial results, capital raises through public offerings, participation in healthcare conferences, and business updates related to the commercial rollout of the next generation Swoop® system and Optive AI™ software.
For those tracking HYPR, the news stream provides insight into the company’s progress in hospital and neurology office adoption, its international expansion, and its collaborations on global brain health projects such as the UNITY initiative. Bookmarking this page allows readers to monitor how Hyperfine’s clinical, regulatory, and financial developments evolve over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Hyperfine, Inc. (NASDAQ: HYPR), pioneer of the Swoop® system, the first FDA-cleared portable MRI system, announced it will report its Q1 2023 financial results on May 11, 2023. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Swoop® provides neuroimaging at the point of care, offering bedside imaging capabilities where traditional MRI access is limited or unavailable. Initially cleared by the FDA in 2020, it is now also approved in Canada, Australia, and other regions, enhancing patient care through accessible diagnostic imaging. Interested investors can access the live audio webcast via the company’s website.
Hyperfine, Inc. (Nasdaq: HYPR) reported fourth quarter and full year 2022 financial results, achieving revenue of $6.8 million for the year, up from $1.5 million in 2021. In Q4 2022, revenue was $1.424 million, compared to $0.436 million in Q4 2021. The net loss for the year was $73.164 million, or $1.04 per share, an increase from $64.851 million or $17.57 per share in the previous year. The company ended the year with $117.472 million in cash. 2023 guidance estimates revenue between $10 to $14 million with a cash burn of $40 to $45 million. Significant achievements included FDA clearances and the installation of 35 commercial systems.
Hyperfine, Inc. (Nasdaq: HYPR), creator of the first FDA-cleared portable MRI system, Swoop®, announced it will report financial results for Q4 and full year 2022 on March 21, 2023. The management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, accessible through their investor page. The Swoop® system, approved for brain imaging in multiple countries, aims to enhance patient care through accessible diagnostic imaging. Since its FDA clearance in 2020, it has revolutionized neuroimaging by bringing bedside MRI capabilities to clinicians, improving diagnosis where conventional MRI is not feasible.
Hyperfine, Inc. (Nasdaq: HYPR) announced FDA 510(k) clearance for an updated version of its Swoop® Portable MR Imaging® system software, enhancing clinical utility in neurocritical care. The new software improves diffusion-weighted imaging (DWI) with a 42% increase in signal-to-noise ratio, essential for diagnosing neurological conditions. This update aims to provide clearer images and better patient care in diagnosing and monitoring stroke progression. The improved software is expected to roll out to customers in March 2023.